Clinical Trial Update: Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD [Phase 2]

View source ↗

Summary

Phase 2 trial update for REL-1017 in major depressive disorder shows safety, tolerability, pharmacokinetics, and symptom response with 7-day dosing at 25 mg or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• REL-1017

Snippet

Sponsor: Relmada Therapeutics, Inc. | Conditions: Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant | Phase 2 | Status: COMPLETED | Results posted: 2021-03-17